Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Shineway Pharmaceutical Group (OTCPK:CSWYY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
China Shineway Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2025 was $-299.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Shineway Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $178.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group EV-to-EBIT Related Terms
China Shineway Pharmaceutical Group EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group EV-to-EBIT Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's EV-to-EBIT falls into.
China Shineway Pharmaceutical Group's current Enterprise Value is $-291.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Shineway Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $178.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group (CSWYY) has a EV-to-EBIT of -1.63 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on China Shineway Pharmaceutical Group and its competitors. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #5 out of 688 companies in the Drug Manufacturers industry, placing it in the top 0.7%.
Is China Shineway Pharmaceutical Group's EV-to-EBIT too high?
China Shineway Pharmaceutical Group's current EV-to-EBIT is -1.63. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #5 out of 688 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #5 out of 688 companies for EV-to-EBIT. This places China Shineway Pharmaceutical Group in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.89, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current EV-to-EBIT is -1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current EV-to-EBIT of -1.63. The stock's GF Value™ is $16.74, compared to a current price of $19.25 — trading 15% above its estimated fair value. The current EV-to-EBIT is -1.63. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current EV-to-EBIT is -1.63 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 15% above its estimated GF Value™ of $16.74.
Key valuation signals for CSWYY:
EV-to-EBIT: -1.63
GF Value™: $16.74 vs. price of $19.25 (15% above fair value)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score
Get the complete analysis for CSWYY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
